Allergan, Inc.

Sesha Neervannan

Chin-Ming Chang

Richard S Graham

Chetan Pujara

Anuradha V Gore

Ke Wu

Kevin S Warner

R Scott Jordan

Sukhon Likitlersuang

Jie Shen

Sai Shankar

Hao Hou

Chetan P Pujara

Jim Jiao

The present disclosure relates to suspension formulations and systems for the treatment of ocular conditions. The suspension formulations can include cyclosporin A and in some embodiments, Form 1 or Form 2 cyclosporin A. A delivery system can be provided that includes two parts, a first part containing particles of cyclosporin and a second part containing other components that can be combined with the first part to make a suspension formulation. The suspension can be injected into the subconjunctival or other periocular space to treat ocular conditions, such as dry eye disease.

Suspension compositions of cyclosporin A for subconjunctival and periocular injection

Ophthalmic products and related methods are described herein. These methods include a stabilizing composition comprising a therapeutically active agent which is separated from a liquid vehicle composition by a barrier. The barrier may be removed to allow the two compositions to mix to provide an ophthalmically acceptable liquid comprising the therapeutically active agent.

Two part formulation system for ophthalmic delivery

Growing community of inventors

Irvine, CA, United States of America

Sesha Neervannan